CliffBio
small molecule

VENLAFAXINE BESYLATE

VENLAFAXINE BESYLATE

Loss of exclusivityMay 2028latest FDA-listed patent expiry
CompanyAlmatica Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameVENLAFAXINE BESYLATE
Active ingredientVENLAFAXINE BESYLATE
StrengthEQ 112.5MG BASE
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2022
Marketing statusRX

Listed patents

PatentExpiresType
7776358May 2028product

More from Almatica Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.